Source: Virtual Congress 2020 – Clinical aspects and new treatment strategies for rare interstitial lung diseases in adults and children
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Tirucherai (Princeton, United States of America), Q. Ruan (Princeton, United States of America), D. Hawthorne (Princeton, United States of America), D. Yu (Raleigh, United States of America), R. Revankar (Princeton, United States of America), E. Charles (Princeton, United States of America). Effect of rifampin, a potent organic-anion-transporting polypeptide inhibitor (OATPi), on the PK of BMS-986278, a lysophosphatidic acid receptor (LPA1) antagonist. 3495

Member's Comments

No comment yet.

Related content which might interest you: BMS-986278, a lysophosphatidic acid 1 (LPA1) receptor antagonist, in healthy participants: A single/multiple ascending dose (SAD/MAD) phase 1 study Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment Year: 2019 Protease-activated receptor 2 (PAR2) stimulation potentiates citric acid induced cough by sensitising the vanilloid receptor-1 (TRPV1) Source: Annual Congress 2003 - Novel drugs under development for the treatment of respiratory diseases Year: 2003 A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via activation of protein phosphatase PP2A Source: Annual Congress 2011 - Phagocytes and dendritic cells Year: 2011 Interaction of retinoid acid receptor-related orphan receptor alpha (RORA) and neuropeptide S receptor 1 (NPSR1) in asthma Source: Annual Congress 2012 - Asthma and the genes: from GWAS to next generation transcriptome analyses Year: 2012 New drugs for pulmonary hypertension Source: Eur Respir Mon 2012; 57: 233-246 Year: 2012 Cystenyl-leukotriene receptor antagonist (LRA) inhibits respiratory burst of human neutrophils Source: Eur Respir J 2003; 22: Suppl. 45, 316s Year: 2003 Molecular and cellular profile of the structurally novel phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004 Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001 Mas receptor antagonist inhibits the pro-resolutive effects of Angiotensin-(1-7) in an experimental model of asthma. Source: International Congress 2019 – Modelling and monitoring of airway diseases Year: 2019 The novel dual D2 dopamine receptor, β2-adrenoceptor agonist Viozan™ (AR-C68397AA) is well tolerated in a dog model Source: Eur Respir J 2001; 18: Suppl. 33, 406s Year: 2001 A new ultra-potent vanilloid receptor 1 (VR1) antagonist abates capsaicin and citric acid induced cough Source: Eur Respir J 2002; 20: Suppl. 38, 190s Year: 2002 The effect of leukotrienes and their receptor antagonists on calcium signalling in the cough receptors transient receptor potential ankyrin 1 (TRPA1) and vanilloid 1 (TRPV1) Source: Annual Congress 2010 - Models of airways disease Year: 2010 The endocannabinoids anandamide and 2-arachidonyl-glycerol (2-AG) induce pulmonary hypertension (PH) in a CB1 receptor independent manner - role of COX-2 and EP1 receptor activation Source: Eur Respir J 2005; 26: Suppl. 49, 733s Year: 2005 Nicotinic alpha-7 receptor stimulation (a7nAChR) inhibited NF-kB/STAT3/SOCS3 pathways in a murine model of asthma. Source: International Congress 2017 – Novel mechanisms and treatments for asthma Year: 2017 Effects of CHF6297, a potent and selective p38a MAPK inhibitor, in murine models of steroid resistant lung inflammation Source: International Congress 2017 – Towards new anti-inflammatory and anti-fibrotic agents Year: 2017 The pro-apoptotic effect of cysteinyl leukotriene receptor (CysLT-R) antagonist montelukast is mediated by CysLT-Rs expression on antigen-stimulated T cells Source: Eur Respir J 2003; 22: Suppl. 45, 100s Year: 2003 Phase 1 evaluation of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, a potent and selective blocker of IL-4Ra Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019 The phosphodiesterase 4 inhibitor SB 207499 selectively inhibits neutrophil functions Source: Eur Respir J 2001; 18: Suppl. 33, 34s Year: 2001 In-vitro evaluation of a new potent, selective pan-Janus kinase (JAK) inhibitor VR588 Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonist Source: Eur Respir J 2007; 30: Suppl. 51, 25s Year: 2007 ErbB receptor regulation by dexamethasone in mouse type II epithelial cells Source: Eur Respir J 2006; 28: 1117-1123 Year: 2006